TransEnterix Adds to Board

TransEnterix Inc. has added William N. Kelley, M.D. to its board of directors. The Research Triangle Park, N.C.-based robotics and flexible instruments company will have a board made up of nine members when Kelley’s appointment becomes effective Jan. 1.

“Kelley is a recognized leader in the medical community, has broad health care experience and will be a tremendous asset to our Board of Directors,” said President and CEO Todd M. Pope. “As we continue to work toward a mid-2015 submission of the U.S. Food and Drug Administration 510(k) application for our Surgibot system and commercialization thereafter, we are confident that Kelley will bring great value as we execute our strategy.”

“I am excited to be joining the TransEnterix Board of Directors,” Said Kelley. “TransEnterix’s patient-side Surgibot system can address a significant unmet need in surgical robotics, and I am impressed by TransEnterix’s strong culture of innovation.”

Kelley has more than 40 years of health care experience including health care system management, education and research, and currently serves as professor of medicine in the Perelman School of Medicine at the University of Pennsylvania. His past experience includes serving as executive vice president of the University of Pennsylvania with responsibilities as CEO for the Medical Center, dean of the School of Medicine, and the Robert G. Dunlop Professor of Medicine and Biochemistry and Biophysics. Kelley has also served as President of the American Society for Clinical Investigation, president of the American College of Rheumatology, chair of the American Board of Internal Medicine, and chair of the Residency Review Committee for Internal Medicine. Kelley currently serves on the board of directors of GenVec, Inc., and previously served on the board of directors of Merck & Co. Inc., Beckman Coulter Inc., Advanced Biosurfaces Inc. and Polymedix Inc. Kelley has served on the editorial boards of 13 medical journals, and his bibliography includes more than 300 publications and 17 books. Kelley received his medical degree from Emory University.

TransEnterix is currently focused on the development and commercialization of the Surgibot system, a minimally invasive surgical robotic system designed to allow the surgeon to be patient-side within the sterile field.